作者: Frank J. Hsu , Beverly A. Teicher , John M. McPherson
DOI: 10.1007/978-1-59745-293-9_46
关键词:
摘要: TGF-β has been implicated as an important factor in the growth, progression, and metastatic potential of advanced cancers. Increased expression production found many neoplasms, including prostate, breast, pancreatic, kidney, liver, colorectal, gastric, esophageal, ovarian, cervical, bladder, myeloma, head neck, thyroid, Kaposi’s, melanoma, non-small cell small lung cancers associated with significantly shorter patient survival. Elevated may augment tumor growth by suppressing immune system, stimulating neovascularization, mediating tumor/stromal interactions that stimulate proliferation, initiating epithelial-mesenchymal transition which contribute to metastasis. Antibodies neutralizing or blocking disrupt a key pathway promotes provide therapeutic opportunity. Anti-TGF-β antibodies become components regimens when combined standard radiation, hormonal, and/or chemotherapies. The ultimate safety efficacy antagonists treatment cancer will be established clinical trials.